Investing.com — Shares of Novo Nordisk (CSE:) continued their upward momentum on Tuesday, rising over 5%, following features on Monday.
This rebound got here after the corporate suffered a steep loss in market worth late final week, shedding almost $125 billion—round 21%—on Friday.
The plunge was triggered by disappointing outcomes from the REDEFINE-1 part 3 trial of its experimental weight problems drug, CagriSema.
The trial evaluated CagriSema, a mixture of cagrilintide (an amylin agonist) and semaglutide (a GLP-1 receptor agonist), for its efficacy in selling weight reduction.
Whereas the therapy led to a complete weight discount of twenty-two.7% after 68 weeks, the placebo-adjusted consequence stood at 20.3%.
Though this was an enchancment over the person parts—cagrilintide reaching 11.8% and semaglutide reaching 16.1%—the outcomes fell wanting expectations.
Novo Nordisk had modeled a 25% weight reduction, elevating considerations in regards to the drug’s prospects as a possible top-tier weight problems therapy.
The trial additionally pointed to challenges with dose escalation, as solely 57% of individuals had reached the best dose by the research’s conclusion.
Adversarial occasions, primarily delicate to reasonable gastrointestinal points, had been famous however didn’t seem extreme sufficient to derail its security profile.
